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Materials and methods 
 
Antibodies and other reagents 
 
“Complete Protease Inhibitor Cocktail” tablets and tetracycline (Tc) hydrochloride were 
from Roche and Sigma, respectively. 5’-Fluoroorotic acid monohydrate (5-FOA) was from 
Zymo Research. Antibodies to the following antigens were used for immunoblotting 
and/or immunoprecipitation: anti-flag M2 monoclonal antibody (Sigma, F1804), 
anti-c-Myc-9E10 monoclonal antibody (Sigma, M5546), anti-hemagglutinin (ha) tag 
monoclonal antibody (Sigma, H6908). Secondary antibodies for immunoblotting were 
Li-Cor IRDye-conjugated goat anti-mouse 800CW (Li-Cor, #C60405-05) or anti-rabbit 
680RD (Li-Cor, C51104-08). Fluorescence patterns were detected and quantified using the 
Odyssey 9120 instrument (Li-Cor, Lincoln, NE). 
 
Yeast strains, media, and genetic techniques 
 
The S. cerevisiae strains used in this study are cited in Table S1. Standard techniques (53, 
54) were employed for strain construction and transformation. S. cerevisiae media included 
YPD medium (1% yeast extract, 2% peptone, 2% glucose; only most relevant components 
are cited); SD medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose); 
SE medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% ethanol); and 
synthetic complete (SC) medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 
2% glucose), plus a mixture of compounds required by a given auxotrophic strain. The 
alternative carbon sources, in either liquid or plate media, were 2% ethanol or 2% glucose. 
The S. cerevisiae strain AH109 was used for two-hybrid assays; the JD52 strain was used 
for split-ubiquitin (Ub) assays; and several BY4741-based strains (see Table S1) were used 
for tetracycline (Tc)-based chase-degradation assays. 
 
Construction of plasmids 
 
The Escherichia coli strains DH5, SUREII (Stratagene), and STBL2 (Invitrogen) 
(Table S1) were used for cloning and maintaining plasmids. Phusion High-Fidelity DNA 
polymerase (New England Biolabs) was employed for PCR. The plasmids and PCR 
primers used in this study are described in Tables S2 and S3, respectively. 
 
pJO629, a parental plasmid used to construct plasmids for the promoter reference 
technique (PRT), was a pRS313-based, low copy (CEN-based) plasmid that expressed a 
test protein and the fDHFRha reference protein from two identical (modified) PTDH3 
promoters (see the main Fig. 2A, B and the main text) (Table S2). Details of pJO629 
construction are available upon request.  
 
We describe here the construction of plasmids other than those used for 2-hybrid assays 
and split-ubiquitin (Ub) assays. Construction of the latter plasmids is described in sections 
below. To produce the low copy pCSJ95 and pCSJ98 plasmids, which expressed, 
respectively, (M)P-Fbp13f and (M)S-Fbp13f in S. cerevisiae from the PTDH3-based 
promoter, the relevant Fbp1 DNA fragments were amplified by PCR from S. cerevisiae 
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genomic DNA using the primer pairs CSJ117/CSJ121 and CSJ120/CSJ121, respectively 
(Table S3). The resulting PCR products were digested with AscI/BglII and ligated into 
AscI/BamHI-cut pJO629 (see above) downstream of its PTDH3-based promoter, yielding 
pCSJ95 and pCSJ98 (Table S2). 
 
To construct pCSJ125 and pCSJ126, which expressed (M)P-Mdh23f and (M)S-Mdh23f in 
S. cerevisiae from the PTDH3-based promoter, the relevant Mdh2 DNA fragments were 
amplified from S. cerevisiae genomic DNA using the primer pairs CSJ170/CSJ171 and 
CSJ172/CSJ171, respectively (Table S3). The resulting PCR products were digested with 
AscI/BamHI and ligated into AscI/BamHI-cut pJO629, yielding pCSJ125 and pCSJ126 
(Table S2). 
 
A two-step procedure was used to construct pCSJ121 and pCSJ122, which expressed 
(M)SP-Pck13f and (M)SS-Pck13f in S. cerevisiae from the PTDH3-based promoter. First, a 
DNA fragment spanning a part of the PCK1 open reading frame (ORF), from +382 to 
+1,647 bp, was amplified from S. cerevisiae genomic DNA using the primer pair 
CSJ162/CSJ163 (Table S3). The amplified fragment was digested with BamHI/BglII and 
ligated into BamHI-cut pJO629, yielding pCSJ120. Second, the relevant PCK1 DNA 
fragments spanning the upstream region of the PCK1 ORF (+1 to +381 bp) was amplified 
from S. cerevisiae genomic DNA using the primer pairs CSJ164/CSJ165 and 
CSJ166/CSJ165, respectively (Table S3). The resulting DNA fragments were digested 
with AscI/BamHI and ligated into AscI/BamHI-cut pCSJ120, yielding pCSJ121 and 
pCSJ122 (Table S2). 
 
To construct pCSJ168, which expressed (M)P-Yhr020w3f in S. cerevisiae from the 
PTDH3-based promoter, the Yhr020w3f DNA fragment was produced by a two-step PCR 
from S. cerevisiae genomic DNA, at first using the primers CSJ237 and CSJ238, and 
thereafter using the primers CSJ237 and CSJ182 (Table S3). The resulting PCR product 
was digested with AscI/NotI and ligated into AscI/NotI-cut pJO629, yielding pCSJ168 
(Table S2). Other plasmids, encoding many analogous constructs (Table S2), were 
constructed similarly to the plasmids described above. Additional details of plasmid 
construction are available upon request. Construction of plasmids for 2-hybrid assays and 
split-Ub assays is described below. All final constructs were verified by DNA sequencing. 
 
Tetracycline (Tc)-chase assays and immunoblotting 
 
Most protein degradation assays of this study employed a version of the promoter 
reference technique (PRT) described in the main Fig. 2A, B and in the main text. These 
PRT-based assays were carried out similarly to the previously described cycloheximide 
(CHX)-chase assays with S. cerevisiae (19, 20), but used low copy pJO629-based plasmids 
expressing a C-terminally flag3-tagged test protein and the long-lived, also tagged 
(fDHFRha) reference protein from a pair of identical (modified) PTDH3 promoters, in a 
setting in which the synthesis of both proteins could be selectively extinguished by the 
addition of tetracycline (Tc) (see the main Fig. 2A, B and the main text). In sum, Tc was 
used to inhibit, in cis, the translation of two mRNAs, the one encoding a test protein and 
the one encoding the fDHFRha reference protein (the main Fig. 2A, B).  
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S. cerevisiae was grown to A600 of 0.8-1.0 at 30C in SC media whose exact composition 
was appropriate for a plasmid(s) carried by the yeast strain. Cells were centrifuged at 
11,200g for 1 min, washed once in pre-warmed SE medium, then resuspended in SE to 
A600 of 1.0 and grew in SE for 16 h at 30C. The resulting cells were harvested by 
centrifugation at 11,200g for 1 min and resuspended in fresh pre-warmed SC to a final 
concentration of A600 of 1.0, followed by the addition of Tc to the final concentration of 
0.2 mM. Control cultures (ethanol-to-ethanol, as distinguished from ethanol-to-glucose) 
were processed identically, except that cells were resuspended in SE medium, instead of 
SC. At indicated times of a chase, a sample of cell suspension (adjusted to correspond to 
1 ml of suspension with A600 of 1.0) was centrifuged for 1 min at 11,200g. The pellet was 
resuspended in 0.8 ml of 0.2 M NaOH and incubated for 20 min on ice, followed by 
centrifugation at 11,200g for 1 min. The pellet was resuspended in 50 l of HU buffer 
(8 M urea, 5% SDS, 1 mM EDTA, 0.1 M dithiothreitol (DTT), 0.005% bromophenol blue, 
0.2 M Tris-HCl, pH 6.8) containing 1x-protease inhibitor cocktail (Roche), and heated for 
10 min at 70C. After centrifugation for 5 min at 11,200g, 15 l of supernatant was 
subjected to SDS-4-10% PAGE, followed by immunoblotting as described previously (20, 
38), using anti-ha (1:2,000) and anti-flag (1:2,000) antibodies as well as a secondary 
antibody (or antibodies) and quantification of resulting (green and/or red) fluorescence 
patterns using the Odyssey 9120 instrument (Li-Cor), its software, and manufacturer’s 
manual. In some experiments, Tc-based, PRT-based chases were carried with cells that 
were grown solely in SC (glucose-containing) media, without an exposure to SE media. 
All Tc-chases in this study were performed at least twice, and yielded results that differed 
by less than 10%. 
 
Two-hybrid binding assays 
 
Two initial plasmids for 2-hybrid assays were pGADCg and pGBKCg (Table S2) (45) 
(Addgene plasmids # 20161 and # 20162). The pCSJ165 plasmid (Table S2), derived from 
pGBKCg, expressed (M)P-Fbp1-Gal4DBD fusion, i.e., the full-length, wild-type 
S. cerevisiae (M)P-Fbp1 that was fused, at its C-terminus, to Gal4DBD, a 2-hybrid-specific 
DNA-binding protein domain (encoded by pGBKCg). pCSJ165 was constructed using the 
Gateway cloning technique (Invitrogen). In the first step, the BP recombination reaction 
was carried out, using Gateway BP clonase II enzyme mix (Invitrogen), the pDonor/Zeo 
vector (Invitrogen) and an attB-containing DNA fragment, produced by PCR from 
S. cerevisiae genomic DNA and the primer pair CSJ227/CSJ228 (Table S3). This step 
yielded pCSJ161, which contained the attL-(M)P-Fbp1 DNA segment. In the second step, 
the LR reaction was carried out with the Gateway LR clonase II enzyme mix (Invitrogen), 
the pCSJ161 plasmid and the pGBKCg vector, yielding the pCSJ165 plasmid (Table S2). 
 
Similar cloning steps were used to construct other, analogous plasmids, which encoded 
2-hybrid-based fusions of test proteins such as (M)X-Fbp1, (M)X-Icl1, (M)X-Mdh2 or 
(M)X-Pck1, and other test proteins as well, whose intended (wild-type or modified) 
N-termini were unobstructed by either DBD or AD domains (Table S2). These 
polypeptides included those containing C-terminally truncated test proteins, which were 
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fused, C-terminally, to the mouse DHFR moiety and the C-terminal (2-hybrid-specific) 
DBD domain (Table S2). 
 
The pCSJ182 plasmid, derived from pGADCg (45) (Table S2), expressed NLS-Gid4-flag3-
Gal4AD fusion, which contained the full-length wild-type S. cerevisiae Gid4 protein 
bearing the C-terminal flag3 tag and the 2-hybrid-specific AD domain. The N-terminus of 
Gid4 was fused to the SV40 nuclear localization signal (NLS), which was encoded by 
pGADCg (45). The pCSJ182 plasmid was also constructed by the two-step Gateway 
cloning technique. First, a BP reaction was carried out, using the pDonor/Zeo vector and 
an attB-containing DNA fragment encoding, in particular, the flag3 tag. This fragment was 
produced by a two-step PCR from S. cerevisiae genomic DNA, at first with the primers 
CSJ248/CSJ249, and thereafter with the primers CSJ248 and CSJ245 (Table S3). This step 
yielded pCSJ177, containing the attL-GID4-flag3 DNA segment. In the second step, the 
LR reaction was carried out, between pCSJ177 and the pGADCg vector, yielding the 
pCSJ182 plasmid (Table S2). Similar cloning steps were used to construct many other, 
analogous plasmids of the present study (Table S2). 
 
To assay for possible interactions of specific GID subunits with the (M)P-Fbp1 protein, 
S. cerevisiae AH109 (Table S1) was cotransformed with pCSJ182 (expressing NLS-Gid4 
flag3-Gal4AD) and either pCSJ165 (expressing (M)P-Fbp1-Gal4DBD) or pCSJ179 
(expressing (M)S-Fbp1-Gal4DBD). Other tested 2-hybrid fusions encoding specific GID 
subunits were pCSJ164 (expressing NLS-Gid1-flag3-Gal4AD), pCSJ181 (expressing 
NLS-Gid2-flag3-Gal4AD), pCSJ234 (expressing NLS-Gid5-flag3-Gal4AD), 
pCSJ267(expressing NLS-Gid7-flag3-Gal4AD), pCSJ268 (expressing NLS-Gid8-flag3-
Gal4AD), and pCSJ183 (expressing NLS-Gid9-flag3-Gal4AD) (Table S2). Analogous 
2-hybrid assays, vis-à-vis specific GID subunits, involved other gluconeogenesis enzymes 
(as 2-hybrid fusions, specifically (M)P-Mdh2-Gal4DBD (pCSJ197) vs. (M)S-Mdh2-
Gal4DBD (pCSJ198), (M)P-Icl1-Gal4DBD (pCSJ227) vs. (M)S-Icl1-Gal4DBD (pCSJ228), and 
(M)SP-Pck1-Gal4DBD (pCSJ199) vs. (M)SS-Pck1-Gal4DBD (pCSJ200) (Table S2). 
 
Other 2-hybrid assays for mapping interactions between Gid4 and (M)P-Fbp1 included 
cotransformations of S. cerevisiae AH109 with pCSJ182 (expressing NLS-Gid4 flag3-
Gal4AD) and plasmids that expressed N-terminal segments (e.g., the first 20 residues) of 
(M)P-Fbp1 fused to DHFR-Gal4DBD (pCSJ327, pCSJ328, and pCSJ348-pCSJ357) 
(Table S2). Additional 2-hybrid assays examined, in similar ways, other gluconeogenesis 
and non-gluconeogenesis proteins fused to DHFR-Gal4DBD (e.g., the plasmids pCSJ334, 
pCSJ335, pCSJ336 and pCSJ337) (Table S2). Positive 2-hybrid controls included plasmids 
that expressed the human WASP-Gal4DBD fusion (pCSJ167) and its known protein ligand 
Cdc42- flag3-Gal4AD (pCSJ166) (Table S2), as described in the legends to specific figures. 
 
Cotransformed cells were plated on SC plates lacking Trp and Leu. Single colonies of 
resulting cotransformants were grown in the otherwise identical liquid medium to a near-
stationary phase, until A600 of ~2.0. The cultures were thereafter serially diluted by 3-fold, 
and 20 μl samples of cell suspensions were spotted onto triple-dropout plates (SC lacking 
Trp, Leu, and His) (55). The plates were incubated at 30C for 2-3 days. As can be seen in 
Fig. S5B (the panel on the right, shown as an example), all examined S. cerevisiae strains 
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could grow on double-dropout plates (lacking only Trp and Leu), but only some strains 
could grow on triple-dropout plates (lacking Trp, Leu and His). Expression of His3, the 
reporter of 2-hybrid assays (44), in otherwise His- cells, was a function of the binding 
affinity between test proteins. 
 
Split-ubiquitin (Ub) binding assays 
 
For the source plasmids and procedures of split-Ub assays see (46, 47, 56-58). The 
pCSJ408 and pCSJ409 plasmids were derived from the Ste14-CUb-R-Ura3-Met313 
plasmid (Table S2) by replacing the Ste14-encoding DNA segment with PCR-produced, 
ClaI/SalI-cut fragments encoding either (M)P-Fbp1 or (M)S-Fbp1. In addition, the PMET17 
promoter of the Ste14-CUB-R-Ura3-Met313 plasmid (Table S2) was replaced by the PCUP1 
promoter, derived from pRS313, yielding the pCSJ473 and pCSJ474 plasmids (Table S2). 
They expressed, respectively, (M)P-Fbp1-CUb-R-Ura3 and (M)S-Fbp1-CUb-R-Ura3 from 
the PCUP1 promoter. 
 
The pCSJ418 plasmid was derived from the NUb-Ubc6-Cup314 plasmid (Table S2) by 
replacing the Ubc6-coding DNA segment with the PCR-produced, BamHI/XhoI-cut, DNA 
fragment encoding Gid4-flag (56). A XhoI/KpnI-cut DNA fragment containing the CYC1 
transcription terminator was inserted after the fragment encoding Gid4-flag, yielding the 
plasmid pCSJ418 (Table S2). It expressed NUb-Gid4-flag from the PCUP1 promoter. 
 
Split-Ub assays for mapping interactions between Gid4 and (M)P-Fbp1 vs. (M)S-Fbp1 
involved cotransformations of S. cerevisiae JD52 (Table S1) with pCSJ418 (expressing 
NUb-Gid4-flag) and the plasmids pCSJ473 and pCSJ474 (Table S2), which expressed, 
respectively, (M)P-Fbp1 or (M)S-Fbp1 linked to the CUb-R-Ura3 moiety (see fig. S7 and 
the main text). Negative controls included otherwise identical split-Ub assays without 
either NUb-encoding or CUb-encoding plasmids.  
 
Split-Ub assays were carried out by plating cotransformed cells on SC plates lacking Trp 
and His. Single colonies of resulting cotransformants were grown in the otherwise identical 
liquid medium to a near-stationary phase (A600 of ~2.0). The resulting cultures were 
thereafter serially diluted by 3-fold, and 20 μl samples of cell suspensions were spotted 
onto triple-dropout plates (lacking Trp, His, and Ura) and containing 0.1 mM CuSO4. The 
plates were incubated at 30C for 1-2 days. All plated strains could grow on double-
dropout plates (lacking only Trp and His), but only strains in which the CUb-R-Ura3 was 
not significantly cleaved (thereby releasing the short-lived R-Ura3) could grow on triple-
dropout plates (lacking Trp, His and Ura), indicating little or no interaction between test 
protein moieties. The same dilutions of cell suspensions were also spotted onto plates 
lacking Trp and His but containing Ura as well as 5’-fluoroorotic acid (FOA; 2 mg/ml) and 
0.1mM CuSO4. The plates were incubated at 30C for 2-3 days. Cell growth patterns on 
FOA plates were opposite to those on FOA-lacking, Ura-lacking plates. See fig. S7, its 
legend, and the main text for additional descriptions of the logic of split-Ub assays and 
their results. 
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Fig. S1. Glycolysis and gluconeogenesis. Gluconeogenesis is, in effect, a reversal of 
glycolysis, in which glucose is converted to pyruvate, with production of ATP and NADH. 
Shown here are key enzymatic steps. The main gluconeogenesis-specific enzymes of 
S. cerevisiae are the Fbp1 fructose-1,6-bisphospatase, the Icl1 isocitrate lyase, the Mdh2 
cytosolic malate dehydrogenase, and the Pck1 phosphoenolpyruvate carboxykinase. (There 
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are also mitochondrial and peroxisomal counterparts of the cytosolic malate 
dehydrogenase.) The cited enzymes are highlighted in red in the diagram. The first three 
enzymes (P-Fbp1, P-Icl1, and P-Mdh2) bear N-terminal Pro, while SP-Pck1 contains Pro 
at position 2, in the N-terminal sequence Ser-Pro. Single two-headed arrows indicate 
substantially reversible steps, which gluconeogenesis and glycolysis have in common. 
Antiparallel double arrows, as well as the set of transitions between pyruvate, 
phosphoenolpyruvate, oxaloacetate and closely related compounds indicate steps whose 
net directions are determined by the relative activities of gluconeogenesis-specific and 
glycolysis-specific enzymes. P-Icl1 and P-Mdh2 are a part of the (also shown) glyoxalate 
cycle (1, 2, 59, 60). 
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Fig. S2. Conditional degradation of P-Fbp1 and designs of 2-hybrid fusions.  
(A) Lane 1, kDa markers. Tetracycline (Tc)-based chases were performed at 30°C 
with wild-type (lanes 2-4) and gid2Δ S. cerevisiae (lanes 5-7) expressing wild-type 
P-Fbp13f in a glucose-lacking, ethanol-containing medium. At the indicated times of a 
chase, cell extracts were prepared, proteins in extracts were fractionated by SDS-PAGE, 
followed by immunoblotting with anti-flag antibody. Note stability of P-Fbp13f in a 
medium containing ethanol as the sole carbon source (see Materials and methods).  
(B) Same as in A but Tc-chases were initiated at the time of transfer of cells from 
ethanol to glucose. Note rapid degradation of P-Fbp13f in wild-type cells (but not in gid2Δ 
cells) in the presence of glucose.  
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(C) Design of X-Fbp1 (X=Pro or other residues) and Gid4 2-hybrid fusions. These 
are examples of many 2-hybrid constructs produced and examined in the present study 
(Table S2). NLS, nuclear localization signal. Gal4-AD, activation domain of the S. 
cerevisiae Gal4 transcriptional activator. Gal4-DBD, DNA-binding domain of the Gal4 
transcriptional activator. Epitope tags (myc and triple flag) are indicated as well (see 
Materials and methods).  
(D) Expression of 2-hybrid test proteins in S. cerevisiae from the PADH1 promoter of 
2-hybrid plasmids (44). Lanes 1-3, 2-hybrid fusions of P-Fbp1, S-Fbp1, and S-Fbp1 (the 
latter S-Fbp1 was from an independent yeast transformant). Lane 4, kDa markers (50, 75, 
and 100 kDa, respectively). Lanes 5 and 6, 2-hybrid fusions of Gid4 and Gid9, 
respectively. Proteins were detected by immunoblotting with anti-myc (lanes 1-3) and 
anti-flag antibodies (lanes 5, 6). 
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Fig. S3. Degradation of P-Fbp1 and SP-Pck1 in wild-type and mutant S. cerevisiae.  
(A) Tc-chases, using PRT-based plasmids expressing P-Fbp13f and the reference 
fDHFRha (see the main Fig. 2A, B), were performed at 30°C during transition from ethanol 
to glucose media with wild-type (lanes 1-4), gid1Δ (lanes 5-8), gid2Δ (lanes 5-8), gid3Δ 
(lanes 9-12), and gid4Δ (lanes 17-20) S. cerevisiae (see Materials and methods). The bands 
of P-Fbp13f and fDHFRha are indicated on the left.  
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(B) Quantification of data shown in the main Fig. 2G (Tc-chases, in wild-type and 
gid2Δ S. cerevisiae, of wild-type SP-Pck13f and its SS-Pck13f mutant). All Tc-chases in 
this study were performed at least twice, and yielded results that differed by less than 10%. 
(C) Quantification of data in A.  
(D) Lane 1, kDa markers. Tc-chases of wild-type SP-Pck13f (lanes 2-5) and its 
SS-Pck13f mutant (lanes 6-9) in wild-type S. cerevisiae during transition from ethanol to 
glucose media (see Materials and Methods). This is an example of independently 
performed Tc-chases of Pck1 that were otherwise the same as some of the Tc-chases in the 
main Fig. 2G.  
(E) Quantification of data in D. All Tc-chases in this study were performed at least 
twice, and yielded results that differed by less than 10%. 
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Fig. S4. 2-hybrid assays of interactions among Gid4, P-Fbp1, derivatives of P-Fbp1, 
specific GID subunits, and other proteins. In this and other figures describing 2-hybrid 
results, Pro residues are in red. Mutant (non-wild-type) residues are in green. Wild-type 
residues (other than Pro) are in blue. Expression of His3, the reporter of 2-hybrid assays 
(44) in otherwise His- cells, is a function of the binding affinity between test proteins. 
Histidine-lacking plates were incubated for 2 days at 30°C to detect the growth of His+ 
cells.  
(A1-4) Gid4 binds to full-length P-Fbp1 but not to the otherwise identical S-Fbp1, 
A-Fbp1, or T-Fbp1. See also the main Fig. 2A1, 2 and Materials and Methods.  
(A5-7) Gid4 binds neither to full-length SP-Pck1, nor to SS-Pck1, nor to PS-Pck1.  
(B1) Human WASP vs. human Cdc42, a previously known protein interaction (61) 
used as a positive control.  
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(B2-7) Assays with full-length P-Fbp1 vs. AD-containing vector alone (a negative 
control), Ssa1 (one of S. cerevisiae Hsp70 proteins), Gid1, Gid2, Gid4 (note the binding of 
P-Fbp1 to Gid4), and Gid9, respectively.  
(C1, 2) Full-length P-Fbp1 binds to Gid4 but not to Gid9.  
(C3, 4) The S-Fbp1 mutant binds neither to Gid4 nor to Gid9.  
(D1, 2) Gid4 binds to full-length P-Fbp1 but not to the otherwise identical S-Fbp1 
(see also A1, 2, and, e.g., the main Fig. 2A1, 2 for the same but independently produced 
results).  
(D3, 4) Gid4 binds to PHSV-Mdh21-20-DHFR-DBD (derived from wild-type 
PHSV-Mdh2) but not to the otherwise identical SHSV-Mdh21-20-DHFR-DBD.  
(D5, 6) Gid4 binds to PIPV-Icl11-20-DHFR-DBD (derived from wild-type 
PIPV-Icl1) but not to the otherwise identical SIPV-Icl11-20-DHFR-DBD.  
(D7) Gid4 binds to PFVK-Oye21-20-DHFR-DBD (see also the main text). Note that 
the binding of Gid4 to PFVK-Oye21-20-DHFR-DBD is significantly weaker than the one 
to, e.g., PHSV-Mdh21-20-DHFR-DBD or PIPV-Icl11-20-DHFR-DBD.  
(D8) Gid4 does not bind to PESR-Pyk21-20-DHFR-DBD (see also the main text).  
(D9, 10) Gid4 binds neither to full-length PTLY-Ald2 nor to its STLY-Ald2 
mutant (see also the main text). 
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Fig. S5. 2-hybrid assays of interactions among Gid4 and N-terminal sequences of 
P-Fbp1 and other proteins. See the legend to fig. S4 for the residue color notations and 
related details.  
(A1, 2) Gid4 binds to full-length PTLV-Fbp1 but not to STLV-Fbp1 (see, e.g., the 
main Fig. 2A1, 2 and fig. S4D1, 2 for the same but independently produced results).  
(A3-7) Gid4 binds to PTLV-G5-DHFR-DBD (bearing the first four N-terminal 
residues of wild-type P-Fbp1) but not to the otherwise identical 2-hybrid fusions bearing 
the indicated non-Pro N-terminal residues.  
(B) The right panel (and the only control panel of this kind that is shown in the 
present study) displays the pattern of cellular growth on a histidine-containing plate, which 
supports the growth of all 2-hybrid-based strains, irrespective of expression levels of the 
His3 2-hybrid reporter. The left panel shows growth patterns of the identical set of strains 
on a histidine-lacking plate, used to detect the results of 2-hybrid assays (see Materials and 
Methods).  
(B1, 2) Same as in A1, 2 but an independent 2-hybrid assay.  
(B3, 4) Gid4 binds to full-length PIPV-Icl1 but not to the otherwise identical 
SIPV-Icl1 (see the main Fig. 2A3, 4 for the same but independently produced results). 
(B5, 6) Gid4 binds to PTLVNGPR-DHFR-DBD (the first eight residues of wild-
type P-Fbp1, in the context of a 2-hybrid fusion) but does not bind to the otherwise 
identical (N-terminal Ser-bearing) STLVNGPR-DHFR-DBD.  
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Fig. S6. 2-hybrid assays of interactions among Fbp1, Pck1, and GID subunits. See 
the legend to fig. S4 for the residue color notations and related details. 
(A1, 2) Gid4 binds to full-length PTLV-Fbp1 but not to the STLV-Fbp1 mutant 
(see, e.g., the main Fig. 2A1, 2 and fig. S4D1, 2 for independently produced results).  
(A3, 4) Gid4 binds to PHSV-G5-DHFR-DBD (bearing the first four N-terminal 
residues of wild-type PHSV-Mdh2) but not to the otherwise identical 
SHSV-G5-DHFR-DBD.  
(A5) Gid4 does not bind to PIPV-G5-DHFR-DBD (bearing the first four 
N-terminal residues of wild-type PIPV-Icl1), despite the presence of N-terminal Pro.  
(A6) Same as in A5 but with SIPV-G5-DHFR-DBD.  
(A7, 8) PTLV-G5-DHFR-DBD (but not STLV-G5-DHFR-DBD) bind to Gid4 (see 
fig. 2D7, 8) for the same but independently produced results). 
(B1, 2) Neither PTLV-Fbp1 nor its STLV-Fbp1 mutant bind to Gid5.  
(B3) Gid7 vs. vector alone (a negative control).  
(B4, 5) Neither PTLV-Fbp1 nor its STLV-Fbp1 mutant bind to Gid7.  
(B6, 7) Neither SPSK-Pck1 nor its SSSK-Pck1 mutant bind to Gid7.  
(C1) Gid8 vs. vector alone (a negative control).  
(C2, 3) Neither PTLV-Fbp1 nor its STLV-Fbp1 mutant bind to Gid8.  
(C4, 5) Neither SPSK-Pck1 nor its SSSK-Pck1 mutant bind to Gid8. 
(C6) Wild-type SPSK-Pck1 does not bind to Gid1. 
(C7) Wild-type SPSK-Pck1 does not bind to Gid2. 
(C8) Wild-type SPSK-Pck1 does not bind to Gid9. 
(C9, 10) Neither SPSK-Pck1 nor its SSSK-Pck1 mutant bind to Gid5. 
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Fig. S7. Verifying specificity of Gid4 binding to P-Fbp1 through the use of 
split-ubiquitin assay.  
(A) Split-Ub assay. In this method, test proteins are expressed as fusions to a 
C-terminal half of Ub (Cub) and to its mutant N-terminal half (Nub), respectively (46, 47). 
An in vivo interaction between test protein moieties would reconstitute a quasi-native Ub 
moiety from Nub and Cub. The readout of this technique is the in vivo cleavage, by 
S. cerevisiae deubiquitylases (DUBs), of a Cub-containing fusion immediately after the 
reconstituted Ub moiety. In the version of the split-Ub assay employed in this study (see 
Materials and methods), the C-terminal moiety of a split-Ub fusion that was released 
through the fusion’s cleavage by DUBs was Arg-Ura3 (R-Ura3) (46, 47). This protein 
moiety, owing to its destabilizing N-terminal Arg residue, was a short-lived substrate of 
the Arg/N-end rule pathway (Fig. 5E). The Ura3 moiety was enzymatically active both in 
the initial (uncleaved) split-Ub fusion and in its cleavage-released R-Ura3 form, but the 
levels of DUB-released R-Ura3 were very low, owing to its degradation by the Arg/N-end 
rule pathway. Cells in which a Ura3-containing split-Ub fusion was largely uncleaved by 
DUBs (signifying little or no interaction between test protein moieties) contained relatively 
high levels of Ura3. Such cells were Ura+ (grew on Ura-lacking plates) and FOA- (did not 
grow on plates containing both uracil and fluoroorotic acid (FOA), since the activity of 
Ura3 converted FOA into a toxic compound). By contrast, in cells in which the bulk of the 
initial Ura3-containing split-Ub fusion was cleaved by DUBs (signifying an interaction 
between test protein moieties), the levels of the (short-lived) R-Ura3 were very low. Such 
cells, therefore, were Ura- and FOA+ (since FOA was largely not converted to a toxic 
compound in these cells).  
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(B) Split-Ub assay was carried out with split-Ub-based fusions containing Gid4 and 
either PTLV-Fbp1 or STLV-Fbp1, as illustrated in A. The relative Ura3 levels were 
assayed, in experiments of this panel, by plating cells on FOA-containing, 
uracil-containing cells. Cell growth on these plates required (sufficiently) low levels of 
Ura3 and signified interaction between test protein moieties. B1: Gid4 binds to 
PTLV-Fbp1 (low levels of Ura3, growth on FOA plates). B2: Gid4 does not bind to 
STLV-Fbp1 (relatively high levels of Ura3, virtually no growth on FOA plates). These 
data were in agreement with the results obtained through the use of 2-hybrid binding 
assays (e.g., Fig. 2 and fig. S4). B3, 4: negative controls. Specifically, the PTLV-Fbp1 and 
STLV-Fbp1 split-Ub fusions (which contained the C-terminal Ura3 moiety) were 
expressed alone, without the split-Ub Gid4 fusion. This resulted in the absence of 
DUB- mediated cleavage of these fusions and therefore in high levels of Ura3 in both 
cases, leading to the absence of growth on FOA plates, as expected. B5: a converse 
negative control. The Gid4 split-Ub fusion (which lacked the Ura3 moiety) was expressed 
together with vector alone, a plasmid that lacked a split-Ub-based X-Fbp1 fusion. The 
complete absence of Ura3, in this case, led to robust cell growth on FOA plates, as 
expected. 
(C) In this panel, the same S. cerevisiae strains as in panel B were assayed by 
growing cells on uracil-lacking plates, yielding, as expected, cell growth patterns opposite 
to those in B (see Materials and methods). 
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Fig. S8. Allowed, suboptimal, and disallowed residues downstream of N-terminal 
proline in Fbp1: positions 2 and 3. 
(A) Row 1, 2: Gid4 binds to the wild-type full-length PTLV-Fbp1 but not to the 
mutant full-length STLV-Fbp1 (see, e.g., the main Fig. 2A1, 2 and fig. S4A1, 2 for the 
same but independently produced results). Rows 3, 4: the 2-hybrid-based Gid4 fusion and 
X-T-L-V-G5-DHFR-DBD fusions (X=P or S). Gid4 binds to P-T-L-V-G5-DHFR-DBD 
but not to S-T-L-V-G5-DHFR-DBD. Other rows: otherwise identical 2-hybrid assays with 
the 2-hybrid-based Gid4 fusion vs. a set of P-X-L-V-G5-DHFR-DBD fusions (X=G, A, S, 
C, V, L, Y, W, D, E, N, Q, H, K, I, M, P, F, R).  
(B) Row 1-4: Same as rows 1-4 in A but independent assays. Other rows: otherwise 
identical 2-hybrid assays with the 2-hybrid-based Gid4 fusion vs. a set of 
P-T-X-V-G5-DHFR-DBD fusions (X=G, A, S, C, V, I, Y, W, D, E, N, Q, H, K, T, M, P, 
F, R). See the main Fig. 4 for a summary of the binding data in figs. S8-S10. 
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Fig. S9. Allowed and disallowed residues downstream of N-terminal proline in Fbp1: 
positions 4 and 5. 
(A) Row 1, 2: Gid4 binds to the wild-type full-length PTLV-Fbp1 but not to the 
mutant full-length STLV-Fbp1 (see, e.g., the main Fig. 2A1, 2 and fig. S4A1, 2 for the 
same but independently produced results). Rows 3, 4: the 2-hybrid-based Gid4 fusion and 
X-T-L-V-G5-DHFR-DBD fusions (X=P, S). Gid4 binds to P-T-L-V-G5-DHFR-DBD but 
not to S-T-L-V-G5-DHFR-DBD. Other rows: otherwise identical 2-hybrid binding assays 
with the 2-hybrid-based Gid4 fusion vs. a set of P-T-L-X-G5-DHFR-DBD fusions (X=G, 
A, S, C, L, I, Y, W, D, E, N, Q, H, K, T, M, P, F, R). 
(B) Row 1-4: Same as rows 1-4 in A but independent assays. Other rows: otherwise 
identical 2-hybrid assays with the 2-hybrid-based Gid4 fusion vs. a set of P-T-L-V-X-
G5-DHFR-DBD fusions (X=G, A, S, T, C, V, L, Y, W, D, E, N, Q, H, K, T, M, P, F, R). 
In this set of fusions, the varying residue at position 5 (occupied by the Asn residue in 
wild-type PTLVN-Fbp1) was inserted between Val-4 and the first Gly residue of the Gly5 
repeat. See the main Fig. 4 for a summary of the binding data in figs. S8-S10. 
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Fig. S10. Allowed and disallowed residues downstream of N-terminal proline in 
Fbp1: position 6. 
Row 1, 2: Gid4 binds to the wild-type full-length PTLV-Fbp1 but not to the mutant 
full-length STLV-Fbp1 (see, e.g., the main Fig. 2A1, 2 and fig. S4A1, 2 for the same but 
independently produced results). Rows 3, 4: the 2-hybrid-based Gid4 fusion and 
X-T-L-V-N-G5-DHFR-DBD fusions (X=P, S). Gid4 binds to P-T-L-V-G5-DHFR-DBD 
but not to S-T-L-V-G5-DHFR-DBD. Other rows: otherwise identical 2-hybrid binding 
assays with the 2-hybrid-based Gid4 fusion vs. a set of P-T-L-V-N-X-G5-DHFR-DBD 
fusions (X=G, A, S, C, L, I, Y, W, D, E, N, Q, H, K, T, M, P, F, R). In this set of fusions, 
the varying residue at position 6 (occupied by the Gly residue in wild-type 
PTLVNG-Fbp1) was inserted between Asn-5 and the first Gly residue of the Gly5 repeat. 
See the main Fig. 4 for a summary of the binding data in figs. S8-S10. 
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Fig. S11. Degradation of wild-type SP-Pck1 and mutant SS-Pck1 in wild-type and 
mutant S. cerevisiae. 
(A) Lane 1, kDa markers. Lanes 2-4, tetracycline (Tc)-based chase, using a 
PRT-based plasmid expressing wild-type SPSK-Pck13f and the reference fDHFRha (see the 
main Fig. 2A, B), was carried out at 30°C during transition from ethanol to glucose media 
with wild-type S. cerevisiae. Lanes 5-7, same as lanes 2-4 but with the mutant 
SSSK-Pck13f. Lanes 8-10, same as lanes 2-4 but in gid4Δ cells. Lanes 11-13, same lanes 8-
10 but with the mutant SSSK-Pck13f. Lanes 14-16, same as lanes 8-10 but in gid2Δ cells. 
Lanes 17-19, same as lanes 14-16 but with the mutant SSSK-Pck13f (see Materials and 
methods). The bands of SXSK-Pck13f (X=P or S) and fDHFRha are indicated on the left.  
(B) Quantification of data in A. All Tc-chases in this study were performed at least 
twice, and yielded results that differed by less than 10%. 
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Fig. S12. 2-hybrid assays that addressed analogies between the substrate-binding 
groove of Gid4 and peptide-binding grooves of MHC I proteins. See the legend to 
fig. S4 for the residue color notations and related details.  
(A1, 2) Gid4 binds to full-length PTLV-Fbp1 but not to the otherwise identical 
STLV-Fbp1 mutant (see, e.g., the main Fig. 2A1, 2 and fig. S4A1, 2 for the same but 
independently produced results).  
(A3, 4) Same as in A1, 2, but with AD-Gid4, in which the 2-hybrid-specific AD 
domain was N-terminal, in contrast to C-terminal AD in other Gid4-based 2-hybrid assays 
of this study. 
(A5, 6) Same as in A3, 4, but with SPSK-Pck1 and its SSSK-Pck1 mutant, 
respectively. Note the absence of binding between Pck1 and either the AD-Gid4 fusion 
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(this panel) or Gid4-AD (e.g., fig. S4A5-7). In contrast, PTLV-Fbp1 bound to Gid4 in 
either one of its configurations, Gid4-AD or AD-Gid4 (A1-4) 
(B1, 2) Same as in A1, 2, but an independent 2-hybrid assay. 
(B3-8) 2-hybrid assays with Gid4 vs. XZSVMNA-G2-DHFR-DBD (X=S, P, A, T; 
Z=P, S). The expressed protein constructs, here, and throughout this study, contained, 
initially, the N-terminal Met residue, which was cotranslationally cleaved off by Met-
aminopeptidases (42). Note the binding of Gid4 to SPSVMNA-G2-DHFR-DBD. Its 
N-terminal (bolded) sequence is identical to that of wild-type SPSK-Pck1, save for the 
replacement of wild-type Lys-4 with Val-4 (see the main text). Note, too, that Gid4 bound 
to SPSVMNA-G2-DHFR-DBD (B3) but not to otherwise identical variants of this fusion 
that contained alterations at positions 1 or 2. 
(C1-4) 2-hybrid assays with Gid4 vs. XSPSVMNA-G2-DHFR-DBD (X=G, A, S, 
T). The N-terminal sequences of these 2-hybrid fusions were one residue longer than that 
of SPSVMNA-G2-DHFR-DBD, which interacted with Gid4 (see B3). See the main text 
for the logic of the assays in C1- C4. 
(C5) Same as in C1- C4 but with Gid4 vs. SPLVMNA-G2-DHFR-DBD. Its 
N-terminal (bolded) sequence, derived from the SPSKMNA N-terminal sequence of wild-
type SPSK-Pck1, contained the Lys-4 → Val-4 mutation (present in all constructs of B and 
C) and also the Ser-3 → Leu-3 mutation.  
(C6) Same as in C5 but with Gid4 vs. PSLVMNA-G2-DHFR-DBD. Its (bolded) 
N-terminal sequence is identical to that of SPLVMNA-G2-DHFR-DBD, save for inversion 
of N-terminal Ser-Pro, resulting in Pro-Ser. Gid4 interacted with both SPSVMNA-G2-
DHFR-DBD of B3 and SPLVMNA-G2-DHFR-DBD of C6, but not with any other 
constructs in B and C. See the main text for the logic of assays in C5-C6. 
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Fig. S13. 2-hybrid assays of interactions among Gid4 and derivatives of SPSK-Pck1. 
See the legend to fig. S4 for the residue color notations and related details.  
(A1, 2) Gid4 binds to full-length PTLV-Fbp1 but not to the otherwise identical 
STLV-Fbp1 mutant (see, e.g., the main Fig. 2A1, 2 and fig. S4A1, 2 for the same but 
independently produced results).  
(A3, 4) Gid4 binds neither to SPSK-Pck11-20-DHFR-DBD (derived from wild-type 
SPSK-Pck1; the first 20 residues of Pck1) nor the otherwise identical mutant 
SSSK-Pck11-20-DHFR-DBD. 
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(B1, 2) Gid4 binds to the full-length PTLV-Fbp1 but not to the otherwise identical 
STLV-Fbp1 mutant (see, e.g., the main Fig. 2A1, 2 and fig. S4A1, 2 for the same but 
independently produced results).  
(B3) Same as in A3 (the absence of Gid4 binding to SPSK-Pck11-20-DHFR-DBD), 
but an independent assay. 
(B4) Same as in A5 (a vector-alone negative control with 
SPSK-Pck11-20-DHFR-DBD), but an independent assay. 
(B5) Gid4 does not bind to PSSK-Pck11-20-DHFR-DBD (a mutant of the wild-type 
N-terminal sequence SPSK of Pck1; its first 20 residues). 
(B6) Gid4 binds to SPSV-Pck11-20-DHFR-DBD (derived from wild-type 
SPSK-Pck1; its first 20 residues) which contains the Lys → Val mutation at position 4 (see 
the main text). 
(B7, 8) Gid4 binds neither to PSSV-Pck11-20-DHFR-DBD nor to 
PSSV-Pck11-20-DHFR-DBD fusions (derived from wild-type SPSK-Pck1; its first 20 
residues), which contain the Lys → Val mutation at position 4. Compare with the result in 
B6. 
(C1, 2) Gid4 binds to full-length PTLV-Fbp1 but not to the otherwise identical 
STLV-Fbp1 mutant (see, e.g., the main Fig. 2A1, 2 and fig. S4A1, 2 for the same but 
independently produced results).  
(C3) Same as in A3 and B3 (the absence of Gid4 binding to “wild-type” 
SPSK-Pck11-20-DHFR-DBD (derived from wild-type Pck1; its first 20 residues). 
(C4) Gid4 binds to SPSV-Pck11-20-DHFR-DBD, which contains the Lys → Val 
mutation at position 4. The same result as in B6. 
(C5) Gid4 binds to the full-length SPSV-Pck1 protein that contains the same single 
Lys → Val mutation at position 4 as in the 2-hybrid fusion of C4.  
(C6, 7) Gid4 binds neither to SPSK-G5-DHFR-DBD nor to 
SPSV-G5-DHFR-DBD, although the latter fusion contains the Lys → Val mutation at 
position 4. These results show that the Lys → Val mutation at position 4 confers the 
binding of Gid4 in the context of the 20 N-terminal residues of Pck1 (see, e.g., B6) but not 
in the context of only four N-terminal residues.  
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Fig. S14. Degradation of P-Fbp1 in cells under glucose-replete conditions.  
(A) Tetracycline (Tc)-based, reference-based chases were performed as described 
in the legend to the main Fig. 2, at 30°C with indicated S. cerevisiae strains expressing 
either PTLV-Fbp13f or STLV-Fbp13f, but with cells that did not undergo glucose 
deprivation. Lane 1, kDa markers. Lanes 2-4, wild-type cells expressing PTLV-Fbp13f. 
Lanes 5-7, same as lanes 2-4 but with gid4Δ cells. Lanes 8-10, same as in lanes 2-4 but 
with STLV-Fbp13f. Lanes 11-13, same as lanes 8-10 but with gid4Δ cells.  
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(B) Quantification of data in A. All chases in this study were performed at least 
twice, and yielded results that differed by less than 10%. The bands of X-Fbp13f and 
fDHFRha are indicated. 
(C) The S. cerevisiae PVSE-Yhr020w prolyl-tRNA synthetase bears N-terminal 
Pro but is long-lived during ethanol → glucose transitions. The 688-residue, C-terminally 
triple-flagged, PVSE-Yhr020w3f was assayed by a tetracycline (Tc)-based, PRT-based 
chase during transition from ethanol to glucose (see the main Fig. 2 and Materials and 
methods). The bands of PVSE-Yhr020w3f and fDHFRha are indicated. See also the main 
text. 
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Fig. S15. N-terminal sequences of S. cerevisiae DNA-encoded proteins that 
bear N-terminal Pro. 
This is one of three consecutive figures (S15-S17) that show the first five residues 
of 295 S. cerevisiae proteins that bear N-terminal Pro (after the cotranslational removal of 
their initial N-terminal Met by Met-aminopeptidases). This set of proteins was defined 
using the ScanProsite (http://prosite.expasy.org/scanprosite/) database, searching for the 
motif “<M-P” (N-terminal Met-Pro) and confining the search to S. cerevisiae, the strain 
S288C. An essentially identical set of proteins could also be identified through a search in 
the SGD (http://www.yeastgenome.org) database. PTLVN-Fbp1, PIPVG-Icl1, and 
PHSVT-Mdh2, the three (out of four) main gluconeogenic enzymes and the identified 
substrates of Gid4 and the rest of the Pro/N-end rule pathway (the main Fig. 1B), are 
highlighted in bold red at the beginning of this diagram. All other N-terminal Pro-bearing 
proteins in figs. S15-S17 are cited alphabetically. 
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Fig. S16. N-terminal sequences of S. cerevisiae DNA-encoded proteins that bear N-
terminal Pro. 
This is the second of three figures (S15-S17) that show the first five residues of 
295 S. cerevisiae proteins that bear N-terminal Pro (after the cotranslational removal of 
their initial N-terminal Met). See the legend to fig. S15 for additional details. 
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Fig. S17. N-terminal sequences of S. cerevisiae DNA-encoded proteins that bear N-
terminal Pro. 
This is the third and last of three figures (S15-S17) that show the first five residues 
of 295 S. cerevisiae proteins that bear N-terminal Pro (after the cotranslational removal of 
their initial N-terminal Met). See the legend to fig. S15 for additional details. 
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Table 1. E. coli and S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
E. coli strains: 
 
DH5a 
 
 
F– Φ80lacZΔM15 Δ(lacZYA-argF) 
U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 
λ– thi-1 gyrA96 relA1 
 
 
Invitrogen 
SUREII endA1 glnV44 thi-1 gyrA96 relA1 lac recB recJ sbcC 
umuC::Tn5 uvrC e14- Δ(mcrCB-hsdSMR-mrr)171 F'[ 
proAB+ lacIq lacZΔM15 Tn10 Amy CmR] 
Stratagene 
STBL2 F- endA1 glnV44 thi-1 recA1 gyrA96 relA1 Δ(lac-
proAB) mcrA Δ(mcrBC-hsdRMS-mrr) λ- 
Invitrogen 
S. cerevisiae 
strains: 
 
BY4741 MATa his3-1 leu2-0 Met15-0 ura3-0 Open Biosystems 
BY4594 GID1Δ::KanMX6 in BY4741 Open Biosystems 
BY3614 GID2Δ::KanMX6 in BY4741 Open Biosystems 
BY6577 GID3Δ::KanMX6 in BY4741 Open Biosystems 
BY3244 GID4Δ::KanMX6 in BY4741 Open Biosystems 
AH109 MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, 
gal4Δ, gal80Δ, LYS2::GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2, URA3::MEL1UAS-
MEL1TATA-lacZ 
Clontech 
JD52 MATa trp1-63 ura3-52 his3-200 leu2-3112. lys2-801 
Varshavsky lab 
collection. 
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Table 2. Plasmids used in this study.  
Plasmid Description Source or Reference 
pGADCg Y2H expression vector. Contains the PADH1 
promoter. Used to produce Gal4-ADha* fusion by 
Gateway cloning. *contains a partial ha epitope 
sequence. 
Addgene 
pGBKCg Y2H expression vector. Contains the PADH1 
promoter. Produces Gal4–DBDmyc fusion by 
Gateway cloning. 
Addgene 
pDONR/Zeo Donor vector for Gateway cloning via BP reaction Invitrogen 
pRS313Cup1 pRS313 derivative containing the PCUP1 promoter Varshavsky lab collection 
Ste14-CUb-R-
Ura3-Met313 
Ste14-CUb-R-Ura3 in pRS313 with PMET17 Varshavsky lab collection 
NUb-Ubc6-
Cup314 
NUb-Ubc6 in pRS314 with PCUP1 Varshavsky lab collection 
pJO629 Yap53flag and flagDHFRha in pRS313 with two 
identical (modified) PTDH3 promoters.  
This study 
pCSJ95 MP-Fbp13flag in pJO629 This study 
pCSJ98 MS-Fbp13flag in pJO629 This study 
pCSJ120 Yap5-Pck1 (+382~1647bp)3flag in pJO629 This study 
pCSJ121 MSP-Pck13flag in pJO629 This study 
pCSJ122 MSS-Pck13flag in pJO629 This study 
pCSJ125 MP-Mdh23flag in pJO629 This study 
pCSJ126 MS-Mdh23flag in pJO629 This study 
pCSJ160 attL-Gid13flag in pDONR/Zeo This study 
pCSJ161 attL-MP-Fbp1 in pDONR/Zeo This study 
pCSJ162 attL-Cdc423flag in pDONR/Zeo This study 
pCSJ163 attL-WASP in pDONR/Zeo This study 
pCSJ164 SV40-NLS-Gid13flag-Gal4-AD in pGADCg This study 
pCSJ165 MP-Fbp1-Gal4-DBD in pGBKCg This study 
pCSJ166 SV40-NLS-Cdc423flag-Gal4-AD in pGADCg This study 
pCSJ167 WASP-Gal4-DBD in pGADCg This study 
pCSJ168 MP-Yhr020w3flag in pJO629 This study 
pCSJ174 attL-MS-Fbp1 in pDONR/Zeo This study 
pCSJ175 attL-Ssa13flag in pDONR/Zeo This study 
pCSJ176 attL-Gid23flag in pDONR/Zeo This study 
pCSJ177 attL-Gid43flag in pDONR/Zeo This study 
pCSJ178 attL-Gid93flag in pDONR/Zeo This study 
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pCSJ179 MS-Fbp1-Gal4-DBD in pGBKCg This study 
pCSJ180 SV40-NLS-Ssa13flag-Gal4-AD in pGADCg This study 
pCSJ181 SV40-NLS-Gid23flag-Gal4-AD in pGADCg This study 
pCSJ182 SV40-NLS-Gid43flag-Gal4-AD in pGADCg This study 
pCSJ183 SV40-NLS-Gid93flag-Gal4-AD in pGADCg This study 
pCSJ193 attL-MP-Mdh2 in pDONR/Zeo This study 
pCSJ194 attL-MS-Mdh2 in pDONR/Zeo This study 
pCSJ195 attL-MSP-Pck1 in pDONR/Zeo This study 
pCSJ196 attL-MSS-Pck1 in pDONR/Zeo This study 
pCSJ197 MP-Mdh2-Gal4-DBD in pGBKCg This study 
pCSJ198 MS-Mdh2-Gal4-DBD in pGBKCg This study 
pCSJ199 MSP-Pck1-Gal4-DBD in pGBKCg This study 
pCSJ200 MSS-Pck1-Gal4-DBD in pGBKCg This study 
pCSJ201 attL-MP-Ald2 in pDONR/Zeo This study 
pCSJ202 attL-MS-Ald2 in pDONR/Zeo This study 
pCSJ205 MP-Ald2-Gal4-DBD in pGBKCg This study 
pCSJ206 MS-Ald2-Gal4-DBD in pGBKCg This study 
pCSJ210 attL-MP-Fbp11-175 in pDONR/Zeo This study 
pCSJ211 attL-MS-Fbp11-175 in pDONR/Zeo This study 
pCSJ216 MP-Fbp11-175-Gal4-DBD in pGBKCg This study 
pCSJ217 MS-Fbp11-175-Gal4-DBD in pGBKCg This study 
pCSJ222 attL-MP-Icl1 in pDONR/Zeo This study 
pCSJ223 attL-MS-Icl1 in pDONR/Zeo This study 
pCSJ224 attL-MPS-Pck1 in pDONR/Zeo This study 
pCSJ225 attL-MP-Pyk2 in pDONR/Zeo This study 
pCSJ226 attL-MS-Pyk2 in pDONR/Zeo This study 
pCSJ227 MP-Icl1-Gal4-DBD in pGBKCg This study 
pCSJ228 MS-Icl1-Gal4-DBD in pGBKCg This study 
pCSJ229 MPS-Pck1-Gal4-DBD in pGBKCg This study 
pCSJ230 MP-Pyk2-Gal4-DBD in pGBKCg This study 
pCSJ231 MS-Pyk2-Gal4-DBD in pGBKCg This study 
pCSJ232 attL-Gid53flag in pDONR/Zeo This study 
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pCSJ234 SV40-NLS-Gid53flag-Gal4-AD in pGADCg This study 
pCSJ261 attL-Gid73flag in pDONR/Zeo This study 
pCSJ263 attL-Gid83flag in pDONR/Zeo This study 
pCSJ267 SV40-NLS-Gid73flag-Gal4-AD in pGADCg This study 
pCSJ268 SV40-NLS-Gid83flag-Gal4-AD in pGADCg This study 
pCSJ290 attL-MP-Fbp11-62 in pDONR/Zeo This study 
pCSJ291 attL-MS-Fbp11-62 in pDONR/Zeo This study 
pCSJ292 attL-MP-Fbp11-87 in pDONR/Zeo This study 
pCSJ293 attL-MS-Fbp11-87 in pDONR/Zeo This study 
pCSJ294 MP-Fbp11-62-Gal4-DBD in pGBKCg This study 
pCSJ295 MS-Fbp11-62-Gal4-DBD in pGBKCg This study 
pCSJ296 MP-Fbp11-87-Gal4-DBD in pGBKCg This study 
pCSJ297 MS-Fbp11-87-Gal4-DBD in pGBKCg This study 
pCSJ323 attL-MV-DHFR in pDONR/Zeo This study 
pCSJ324 attL-MP-Fbp11-20-DHFR in pDONR/Zeo This study 
pCSJ325 attL-MS-Fbp11-20-DHFR in pDONR/Zeo This study 
pCSJ326 MV-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ327 MP-Fbp11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ328 MS-Fbp11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ330 attL-MP-Mdh21-20-DHFR in pDONR/Zeo This study 
pCSJ331 attL-MS-Mdh21-20-DHFR in pDONR/Zeo This study 
pCSJ332 attL-MP-Icl11-20-DHFR in pDONR/Zeo This study 
pCSJ333 attL-MS-Icl11-20-DHFR in pDONR/Zeo This study 
pCSJ334 MP-Mdh21-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ335 MS-Mdh21-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ336 MP-Icl11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ337 MS-Icl11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ358 attL-MP-Oye21-20-DHFR in pDONR/Zeo This study 
pCSJ359 attL-MP-Pyk21-20-DHFR in pDONR/Zeo This study 
pCSJ360 MP-Oye1-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ361 MP-Pyk21-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ362 attL-MA-Fbp1 in pDONR/Zeo This study 
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pCSJ363 attL-MT-Fbp1 in pDONR/Zeo This study 
pCSJ364 MA-Fbp1-Gal4-DBD in pGBKCg This study 
pCSJ365 MT-Fbp1-Gal4-DBD in pGBKCg This study 
pCSJ370 attL-MP-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ371 attL-MS-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ372 attL-MP-Fbp11-3-(Gly)7-DHFR in pDONR/Zeo This study 
pCSJ373 attL-MS-Fbp11-3-(Gly)7-DHFR in pDONR/Zeo This study 
pCSJ374 attL-MP-(Gly)8-DHFR in pDONR/Zeo This study 
pCSJ375 attL-MS-(Gly)8-DHFR in pDONR/Zeo This study 
pCSJ376 MP-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ377 MS-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ378 MP-Fbp11-3-(Gly)7-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ379 MS-Fbp11-3-(Gly)7-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ380 MP-(Gly)8-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ381 MS-(Gly)8-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ408 MP-Fbp1-CUb-R-Ura3 in pRS313 with PMET17 This study 
pCSJ409 MS-Fbp1-CUb-R-Ura3 in pRS313 with PMET17 This study 
pCSJ418 NUb-Gid4flag in pRS314 with PCUP1 This study 
pCSJ423 attL-MSP-Pck11-20-DHFR in pDONR/Zeo This study 
pCSJ424 attL-MSS-Pck11-20-DHFR in pDONR/Zeo This study 
pCSJ425 MSP-Pck11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ426 MSS-Pck11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ435 attL-MPSSK-Pck11-20-DHFR in pDONR/Zeo This study 
pCSJ436 attL-MSPSV-Pck11-20-DHFR in pDONR/Zeo This study 
pCSJ437 attL-MPSSV-Pck11-20-DHFR in pDONR/Zeo This study 
pCSJ438 MPSSK-Pck11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ439 MSPSV-Pck11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ440 MPSSV-Pck11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ445 attL-MPG-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ446 attL-MPA-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ447 attL-MPS-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ448 attL-MPC-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
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pCSJ449 attL-MPV-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ450 attL-MPL-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ451 attL-MPY-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ452 attL-MPW-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ453 attL-MPD-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ454 attL-MPE-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ455 attL-MPN-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ456 attL-MPQ-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ457 attL-MPH-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ458 attL-MPK-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ459 MPG-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ460 MPA-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ461 MPS-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ462 MPC-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ463 MPV-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ464 MPL-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ465 MPY-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ466 MPW-Fbp11-5-(Gly)5-DHFR-Gal4-DBD 
in pGBKCg 
This study 
pCSJ467 MPD-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ468 MPE-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ469 MPN-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ470 MPQ-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ471 MPH-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ472 MPK-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ473 MP-Fbp1-CUb-R-Ura3 in pRS313 with PCUP1 This study 
pCSJ474 MS-Fbp1-CUb-R-Ura3 in pRS313 with PCUP1 This study 
pCSJ475 attL-MPTG-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ476 attL-MPTA-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ477 attL-MPTS-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ478 attL-MPTC-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ479 attL-MPTV-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
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pCSJ480 attL-MPTI-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ481 attL-MPTY-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ482 attL-MPTW-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ483 attL-MPTD-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ484 attL-MPTE-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ485 attL-MPTN-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ486 attL-MPTQ-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ487 attL-MPTH-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ488 attL-MPTK-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ489 MPTG-Fbp11-5-(Gly)5-DHFR-Gal4-DBD 
in pGBKCg 
This study 
pCSJ490 MPTA-Fbp11-5-(Gly)5-DHFR-Gal4-DBD 
in pGBKCg 
This study 
pCSJ491 MPTS-Fbp11-5-(Gly)5-DHFR-Gal4-DBD 
in pGBKCg 
This study 
pCSJ492 MPTC-Fbp11-5-(Gly)5-DHFR-Gal4-DBD 
in pGBKCg 
This study 
pCSJ493 MPTV-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ494 MPTI-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ495 MPTY-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ496 MPTW-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ497 MPTD-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ498 MPTE-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ499 MPTN-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ500 MPTQ-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ501 MPTH-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ502 MPTK-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ503 attL-MSSSV-Pck11-20-DHFR in pDONR/Zeo This study 
pCSJ504 MSSSV-Pck11-20-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ513 attL-MPTLG-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
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pCSJ514 attL-MPTLA-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ515 attL-MPTLS-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ516 attL-MPTLC-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ517 attL-MPTLL-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ518 attL-MPTLI-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ519 attL-MPTLY-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ520 attL-MPTLW-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ521 attL-MPTLD-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ522 attL-MPTLE-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ523 attL-MPTLN-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ524 attL-MPTLQ-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ525 attL-MPTLH-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ526 attL-MPTLK-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ527 MPTLG-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ528 MPTLA-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ529 MPTLS-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ530 MPTLC-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ531 MPTLL-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ532 MPTLI-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ533 MPTLY-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ534 MPTLW-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ535 MPTLD-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ536 MPTLE-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ537 MPTLN-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ538 MPTLQ-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ539 MPTLH-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ540 MPTLK-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  This study 
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in pGBKCg 
pCSJ541 attL-MSPSV-Pck1 in pDONR/Zeo This study 
pCSJ542 attL-MSPSK-Pck11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ543 attL-MSPSV-Pck11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ545 MSPSV-Pck1-Gal4-DBD in pGBKCg This study 
pCSJ546 MSPSK-Pck11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ547 MSPSV-Pck11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ549 attL-MPI-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ550 attL-MPM-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ551 attL-MPP-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ552 attL-MPF-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ553 attL-MPR-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ554 MPI-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ555 MPM-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ556 MPP-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ557 MPF-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ558 MPR-Fbp11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ559 attL-MPTT-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ560 attL-MPTM-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ561 attL-MPTP-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ562 attL-MPTF-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ563 attL-MPTR-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ564 MPTT-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ565 MPTM-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ566 MPTP-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ567 MPTF-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ568 MPTR-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ569 attL-MPTLT-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ570 attL-MPTLM-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
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pCSJ571 attL-MPTLP-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ572 attL-MPTLF-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ573 attL-MPTLR-Fbp11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ574 MPTLT-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ575 MPTLM-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ576 MPTLP-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ577 MPTLF-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ578 MPTLR-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ579 attL-MPTLV-Fbp11-5-G-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ580 attL-MPTLV-Fbp11-5-A-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ581 attL-MPTLV-Fbp11-5-S-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ582 attL-MPTLV-Fbp11-5-T-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ583 attL-MPTLV-Fbp11-5-C-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ584 attL-MPTLV-Fbp11-5-V-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ585 attL-MPTLV-Fbp11-5-L-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ586 attL-MPTLV-Fbp11-5-Y-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ587 attL-MPTLV-Fbp11-5-W-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ588 attL-MPTLV-Fbp11-5-D-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ589 attL-MPTLE-Fbp11-5-A-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ590 attL-MPTLV-Fbp11-5-N-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ591 attL-MPTLV-Fbp11-5-Q-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ592 attL-MPTLV-Fbp11-5-H-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ593 attL-MPTLV-Fbp11-5-K-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ594 attL-MPTLV-Fbp11-5-I-(Gly)5-DHFR
in pDONR/Zeo 
This study 
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pCSJ595 attL-MPTLV-Fbp11-5-M-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ596 attL-MPTLV-Fbp11-5-P-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ597 attL-MPTLV-Fbp11-5-F-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ598 attL-MPTLV-Fbp11-5-R-(Gly)5-DHFR
in pDONR/Zeo 
This study 
pCSJ599 MPTLV-Fbp11-5-G-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ600 MPTLV-Fbp11-5-A-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ601 MPTLV-Fbp11-5-S-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ602 MPTLV-Fbp11-5-T-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ603 MPTLV-Fbp11-5-C-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ604 MPTLV-Fbp11-5-V-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ605 MPTLV-Fbp11-5-L-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ606 MPTLV-Fbp11-5-Y-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ607 MPTLV-Fbp11-5-W-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ608 MPTLV-Fbp11-5-D-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ609 MPTLV-Fbp11-5-E-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ610 MPTLV-Fbp11-5-N-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ611 MPTLV-Fbp11-5-Q-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ612 MPTLV-Fbp11-5-H-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ613 MPTLV-Fbp11-5-K-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ614 MPTLV-Fbp11-5-I-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ615 MPTLV-Fbp11-5-M-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ616 MPTLV-Fbp11-5-P-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ617 MPTLV-Fbp11-5-F-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
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pCSJ618 MPTLV-Fbp11-5-R-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ619 attL-MP-Mdh21-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ620 attL-MS-Mdh21-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ621 attL-MP-Icl11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ622 attL-MS-Icl11-5-(Gly)5-DHFR in pDONR/Zeo This study 
pCSJ623 MP-Mdh21-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ624 MS-Mdh21-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ625 MP-Icl11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ626 MS-Icl11-5-(Gly)5-DHFR-Gal4-DBD in pGBKCg This study 
pCSJ629 attL-MSPSV-Pck11-8-(Gly)2-DHFR in pDONR/Zeo This study 
pCSJ632 MSPSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ643 MSSSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ644 MPSSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ645 MAPSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ646 MTPSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ647 MPPSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ648 MGSPSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ649 MASPSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ650 MSSPSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ651 MTSPSSV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ652 MSPLV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ653 MPSLV-Pck11-8-(Gly)2-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ654 MGTLV-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ655 MVTLV-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ656 MCTLV-Fbp11-5-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ681 MPTLVN-Fbp11-6-G-(Gly)5-DHFR-Gal4-DBD  This study 
44 
 
in pGBKCg 
pCSJ682 MPTLVN-Fbp11-6-A-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ683 MPTLVN-Fbp11-6-S-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ684 MPTLVN-Fbp11-6-T-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ685 MPTLVN-Fbp11-6-C-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ686 MPTLVN-Fbp11-6-V-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ687 MPTLVN-Fbp11-6-L-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ688 MPTLVN-Fbp11-6-Y-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ689 MPTLVN-Fbp11-6-W-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ690 MPTLVN-Fbp11-6-D-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ691 MPTLVN-Fbp11-6-E-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ692 MPTLVN-Fbp11-6-N-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ693 MPTLVN-Fbp11-6-Q-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ694 MPTLVN-Fbp11-6-H-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ695 MPTLVN-Fbp11-6-K-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ696 MPTLVN-Fbp11-6-I-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ697 MPTLVN-Fbp11-6-M-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ698 MPTLVN-Fbp11-6-P-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ699 MPTLVN-Fbp11-6-F-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
pCSJ700 MPTLVN-Fbp11-6-R-(Gly)5-DHFR-Gal4-DBD  
in pGBKCg 
This study 
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Table S3. PCR primers used in this study. 
Primer Sequence (5’ to 3’) 
XW50 GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGCCATTTGTTAAGGA
CTTTAAGCCAC 
CSJ117 ATATATGGCGCGCCATGCCAACTCTAGTAAATGGACC 
CSJ120 ATATATGGCGCGCCATGTCTACTCTAGTAAATGGACC 
CSJ121 ATATATAGATCTCTGTGACTTGCCAATATG 
CSJ162 GCAGGATGGGATCCAAAATACAG 
CSJ163 ATATATAGATCTCTCGAATTGAGGACCAGCGGC 
CSJ164 ATATATGGCGCGCCATGTCCCCTTCTAAAATGAATGC 
CSJ165 CTGTATTTTGGATCCCATCCTGC 
CSJ166 ATATATGGCGCGCCATGTCCTCTTCTAAAATGAATGCTACAGTAG 
CSJ170 ATATATGGCGCGCCATGCCTCACTCAGTTACACCATCCATAG 
CSJ171 ATATATGGATCCAGATGATGCAGATCTCGATGCAACGAATTC 
CSJ172 ATATATGGCGCGCCATGTCTCACTCAGTTACACCATCCATAG 
CSJ225 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTGAATATATGGAT
GACG 
CSJ226 GGGGACCACTTTGTACAAGAAAGCTGGGTCTTTGTCATCATCATCCTTA
TAG 
CSJ227 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAAA
TGGACC 
CSJ228 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTGTGACTTGCCAATATG
GTCTA 
CSJ229 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCAGACAATTAAGTG
TGTTG 
CSJ230 CTTGTCATCGTCATCCTTGTAATCGATATCATGATCTTTATAATCACCGT
CATGGTCTTTATAGTCCCCGGGTAGCAGCACACACCTGCGGCTCTTC 
CSJ231 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTTGTCATCGTCATCCTTG
TAA 
CSJ232 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAATAGTGGCCCTGG
CCCTG 
CSJ233 GGGGACCACTTTGTACAAGAAAGCTGGGTCGTCATCCCATTCATCATCC
TCT 
CSJ237 ATATATGGCGCGCCATGCCTGTTTCGGAAGCGTTTGCC 
CSJ238 CATGATCTTTATAATCACCGTCATGGTCTTTATAGTCGGATCCATAAGA
ACGACCGAACATACAGTAATTGA 
CSJ242 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTACTCTAGTAAA
TGGACC 
CSJ243 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCAAAAGCTGTCGG
TATTG 
CSJ244 TTTGTCATCATCATCCTTATAGTCAATGTCATGATCCTTGTAATCACCAT
CATGATCCTTGTAATCCCCGGGATCAACTTCTTCAACGGTTGGACC 
CSJ245 GGGGACCACTTTGTACAAGAAAGCTGGGTCTTTGTCATCATCATCCTTA
46 
 
TAG 
CSJ246 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTGAATTACTAGA
TAGCT 
CSJ247 TTTGTCATCATCATCCTTATAGTCAATGTCATGATCCTTGTAATCACCAT
CATGATCCTTGTAATCCCCGGGAAGCATAACAAAACGAACCTTT 
CSJ248 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGATCAATAATCCTAA
GGTAG 
CSJ249 TTTGTCATCATCATCCTTATAGTCAATGTCATGATCCTTGTAATCACCAT
CATGATCCTTGTAATCCCCGGGAGCAAACTCAAAAGAACAATCAC 
CSJ250 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGCAGAGAAATCAAT
ATTTAATG 
CSJ251 TTTGTCATCATCATCCTTATAGTCAATGTCATGATCCTTGTAATCACCAT
CATGATCCTTGTAATCCCCGGGGGTTGGGTACATTTTGATAGAATC 
CSJ261 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTCACTCAGTTAC
ACCATC 
CSJ262 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTCACTCAGTTAC
ACCATC 
CSJ263 GGGGACCACTTTGTACAAGAAAGCTGGGTCAGATGATGCAGATCTCGA
TGCAA 
CSJ264 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCCCTTCTAAAAT
GAATGC 
CSJ265 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCTCTTCTAAAAT
GAATGC 
CSJ266 GGGGACCACTTTGTACAAGAAAGCTGGGTCCTCGAATTGAGGACCAGC
GGCTA 
CSJ267 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTACCTTGTATAC
TGATAT 
CSJ268 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTACCTTGTATACT
GATAT 
CSJ269 GGGGACCACTTTGTACAAGAAAGCTGGGTCGTTGTCCAAAGAGAGATT
TATGT 
CSJ273 GGGGACCACTTTGTACAAGAAAGCTGGGTCGGCATAGCAAGCGGCTAC
CATTT 
CSJ277 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTATCCCCGTTGG
AAATAC 
CSJ278 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTATCCCCGTTGG
AAATAC 
CSJ279 GGGGACCACTTTGTACAAGAAAGCTGGGTCTTTCTTTACGCCATTTTCT
TTGA 
CSJ280 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTTCCTCTAAAAT
GAATGC 
CSJ281 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAGAGTCCAGATT
GCAGAG 
CSJ282 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTGAGTCCAGATT
GCAGAGAC 
47 
 
CSJ283 GGGGACCACTTTGTACAAGAAAGCTGGGTCGAATTCTTGACCAACAGT
AGAAA 
CSJ284 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGACGGTGGCTTATTC
CCTAGAG 
CSJ285 TTTGTCATCATCATCCTTATAGTCAATGTCATGATCCTTGTAATCACCAT
CATGATCCTTGTAATCCCCGGGTTTAACTTTCAAAAGCAGGTCCA 
CSJ321 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCACACACTAATAA
GATCGC 
CSJ322 TTTGTCATCATCATCCTTATAGTCAATGTCATGATCCTTGTAATCACCAT
CATGATCCTTGTAATCCCCGGGATTTCTTGAAATTTTCCAGATTT 
CSJ323 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGACTATATCTACTCTT
AGTAAC 
CSJ324 TTTGTCATCATCATCCTTATAGTCAATGTCATGATCCTTGTAATCACCAT
CATGATCCTTGTAATCCCCGGGGTTTTCGACCCTAGGAACCCCTA 
CSJ347 GGGGACCACTTTGTACAAGAAAGCTGGGTCAGCACGTCTGATGGTGTG
AGATAC 
CSJ348 GGGGACCACTTTGTACAAGAAAGCTGGGTCTAGAACGTCCAACTTCTTT
TGCTG 
CSJ361 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGTTCGACCATTGAA
CTGCATC 
CSJ362 GGGGACCACTTTGTACAAGAAAGCTGGGTCGTCTTTCTTCTCGTAGACT
TC 
CSJ363 ATGCCAACTCTAGTAAATGGACCAAGAAGAGACTCTACCGAAGGGTTT
GATACCGATATCGTTCGACCATTGAACTGC 
CSJ364 ATGTCTACTCTAGTAAATGGACCAAGAAGAGACTCTACCGAAGGGTTT
GATACCGATATCGTTCGACCATTGAACTGC 
CSJ375 ATGCCTCACTCAGTTACACCATCCATAGAACAAGATTCGTTAAAAATTG
CCATTTTAGGT GTTCGACCATTGAACTGC 
CSJ376 ATGTCTCACTCAGTTACACCATCCATAGAACAAGATTCGTTAAAAATTG
CCATTTTAGGT GTTCGACCATTGAACTGC 
CSJ377 ATGCCTATCCCCGTTGGAAATACGAAGAACGATTTTGCAGCTTTACAAG
CAAAACTAGAT GTTCGACCATTGAACTGC 
CSJ378 ATGTCTATCCCCGTTGGAAATACGAAGAACGATTTTGCAGCTTTACAAG
CAAAACTAGAT GTTCGACCATTGAACTGC 
CSJ379 ATGCCATTTGTTAAGGACTTTAAGCCACAAGCTTTGGGTGACACCAACT
TATTCAAACCA GTTCGACCATTGAACTGC 
CSJ380 ATGCCAGAGTCCAGATTGCAGAGACTAGCTAATTTGAAAATAGGAACT
CCGCAGCAGCTC GTTCGACCATTGAACTGC 
CSJ381 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGGCTACTCTAGTAAA
TGGACC 
CSJ382 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGACTACTCTAGTAAA
TGGACC 
CSJ386 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAGG
AGGAGGGGGTGGAGTTCGACCATTGAACTGCATC 
CSJ387 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTACTCTAGTAGG
AGGAGGGGGTGGAGTTCGACCATTGAACTGCATC 
48 
 
CSJ388 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTGGAGGAGG
GGGTGGAGGCGGAGTTCGACCATTGAACTGCATC 
CSJ389 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTACTGGAGGAGG
GGGTGGAGGCGGAGTTCGACCATTGAACTGCATC 
CSJ390 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAGGAGGAGGGG
GTGGAGGCGGAGGAGTTCGACCATTGAACTGCATC 
CSJ391 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTGGAGGAGGGGG
TGGAGGCGGAGGAGTTCGACCATTGAACTGCATC 
CSJ418 ATATATATCGATATGCCAACTCTAGTAAATGG 
CSJ419 ATATATGTCGACCCACTCTGTGACTTGCCAATATGG 
CSJ420 ATATATATCGATATGTCTACTCTAGTAAATGG 
CSJ440 ATGTCCCCTTCTAAAATGAATGCTACAGTAGGATCTACTTCCGAAGTTG
AACAAAAAATCGTTCGACCATTGAACTGC 
CSJ441 ATGTCCTCTTCTAAAATGAATGCTACAGTAGGATCTACTTCCGAAGTTG
AACAAAAAATCGTTCGACCATTGAACTGC 
CSJ453 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTTCCTCTAAAAT
GAATGCTACAGTAG 
CSJ454 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCCCTTCTGTAAT
GAATGCTACAGTAG 
CSJ455 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTTCCTCTGTAAT
GAATGCTACAGTAG 
CSJ460 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAGGTCTAGTAGG
AGGAGGGGGT 
CSJ461 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAGCTCTAGTAGG
AGGAGGGGGT 
CSJ462 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCATCTCTAGTAGG
AGGAGGGGGT 
CSJ463 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCATGTCTAGTAGG
AGGAGGGGGT 
CSJ464 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAGTTCTAGTAGG
AGGAGGGGGT 
CSJ465 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCATTGCTAGTAGG
AGGAGGGGGT 
CSJ466 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCATATCTAGTAGG
AGGAGGGGGT 
CSJ467 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCATGGCTAGTAGG
AGGAGGGGGT 
CSJ468 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAGATCTAGTAGG
AGGAGGGGGT 
CSJ469 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAGAACTAGTAGG
AGGAGGGGGT 
CSJ470 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAAATCTAGTAGG
AGGAGGGGGT 
CSJ471 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCACAACTAGTAGG
AGGAGGGGGT 
49 
 
CSJ472 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCACATCTAGTAGG
AGGAGGGGGT 
CSJ473 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAAAACTAGTAGG
AGGAGGGGGT 
CSJ474 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTGGTGTAGG
AGGAGGGGGT 
CSJ475 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTGCTGTAGG
AGGAGGGGGT 
CSJ476 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTTCTGTAGG
AGGAGGGGGT 
CSJ477 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTTGTGTAGG
AGGAGGGGGT 
CSJ478 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTGTTGTAGG
AGGAGGGGGT 
CSJ479 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTATTGTAGG
AGGAGGGGGT 
CSJ480 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTTATGTAGG
AGGAGGGGGT 
CSJ481 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTTGGGTAGG
AGGAGGGGGT 
CSJ482 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTGATGTAGG
AGGAGGGGGT 
CSJ483 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTGAAGTAGG
AGGAGGGGGT 
CSJ484 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTAATGTAGG
AGGAGGGGGT 
CSJ485 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCAAGTAGG
AGGAGGGGGT 
CSJ486 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCATGTAGG
AGGAGGGGGT 
CSJ487 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTAAAGTAGG
AGGAGGGGGT 
CSJ488 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCTCCTCTGTAAT
GAATGCTACAGTAG 
CSJ494 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGGTGG
AGGAGGGGGTGG 
CSJ495 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGCTGG
AGGAGGGGGTGG 
CSJ496 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTATCTGG
AGGAGGGGGTGG 
CSJ497 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTATGTGG
AGGAGGGGGTGG 
CSJ498 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTATTGGG
AGGAGGGGGTGG 
CSJ499 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAATTGG
AGGAGGGGGTGG 
50 
 
CSJ500 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTATATGG
AGGAGGGGGTGG 
CSJ501 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTATGGGG
AGGAGGGGGTGG 
CSJ502 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGATGG
AGGAGGGGGTGG 
CSJ503 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGAAGG
AGGAGGGGGTGG 
CSJ504 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAAATGG
AGGAGGGGGTGG 
CSJ505 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTACAAGG
AGGAGGGGGTGG 
CSJ506 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTACATGG
AGGAGGGGGTGG 
CSJ507 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAAAAGG
AGGAGGGGGTGG 
CSJ508 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCCCTTCTGTTATG
AATGCTACAGT 
CSJ509 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCCCTTCTAAAGG
AGGAGGGGGTGG 
CSJ510 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCCCTTCTGTTGG
AGGAGGGGGTGG 
CSJ512 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAATTCTAGTAGG
AGGAGGGGGT 
CSJ513 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAATGCTAGTAGG
AGGAGGGGGT 
CSJ514 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCACCACTAGTAGG
AGGAGGGGGT 
CSJ515 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCATTTCTAGTAGG
AGGAGGGGGT 
CSJ516 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAAGACTAGTAGG
AGGAGGGGGT 
CSJ517 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTACTGTAGG
AGGAGGGGGT 
CSJ518 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTATGGTAGG
AGGAGGGGGT 
CSJ519 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCCAGTAGG
AGGAGGGGGT 
CSJ520 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTTTTGTAGG
AGGAGGGGGT 
CSJ521 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTAGAGTAGG
AGGAGGGGGT 
CSJ522 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAACTGG
AGGAGGGGGTGG 
CSJ523 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAATGGG
AGGAGGGGGTGG 
51 
 
CSJ524 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTACCAGG
AGGAGGGGGTGG 
CSJ525 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTATTTGG
AGGAGGGGGTGG 
CSJ526 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAAGAGG
AGGAGGGGGTGG 
CSJ527 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAGG
TGGAGGAGGGGGTGG 
CSJ528 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAGC
TGGAGGAGGGGGTGG 
CSJ529 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTATC
TGGAGGAGGGGGTGG 
CSJ530 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAAC
TGGAGGAGGGGGTGG 
CSJ531 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTATG
TGGAGGAGGGGGTGG 
CSJ532 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAGT
TGGAGGAGGGGGTGG 
CSJ533 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTATT
GGGAGGAGGGGGTGG 
CSJ534 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTATA
TGGAGGAGGGGGTGG 
CSJ535 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTATG
GGGAGGAGGGGGTGG 
CSJ536 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAGA
TGGAGGAGGGGGTGG 
CSJ537 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAGA
AGGAGGAGGGGGTGG 
CSJ538 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAAA
TGGAGGAGGGGGTGG 
CSJ539 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTACA
AGGAGGAGGGGGTGG 
CSJ540 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTACA
TGGAGGAGGGGGTGG 
CSJ541 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAAA
AGGAGGAGGGGGTGG 
CSJ542 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAAT
TGGAGGAGGGGGTGG 
CSJ543 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAAT
GGGAGGAGGGGGTGG 
CSJ544 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTACC
AGGAGGAGGGGGTGG 
CSJ545 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTATT
TGGAGGAGGGGGTGG 
CSJ546 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCAACTCTAGTAAG
AGGAGGAGGGGGTGG 
52 
 
CSJ547 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTCACTCAGTTGG
AGGAGGGGGT 
CSJ548 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTCACTCAGTTGG
AGGAGGGGGT 
CSJ549 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGCCTATCCCCGTTGG
AGGAGGGGGT 
CSJ550 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCTATCCCCGTTGG
AGGAGGGGGT 
CSJ553 ATGTCCCCTTCTGTTATGAATGCTGGAGGAGTTCGACCATTGAACTGC 
CSJ554 GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCCCCTTCTGTTATG
AATG 
CSJ564 GGTCTTCTCGAGGAAAAATCAGTAGAAATAG 
CSJ595 ATATATACTAGTTTCATGTCCTCTTCTGTTATGAATGCTGGAGGA 
CSJ596 ATATATACTAGTTTCATGCCATCTTCTGTTATGAATGCTGGAGGA 
CSJ597 ATATATACTAGTTTCATGGCTCCTTCTGTTATGAATGCTGGAGGA 
CSJ598 ATATATACTAGTTTCATGACTCCTTCTGTTATGAATGCTGGAGGA 
CSJ599 ATATATACTAGTTTCATGCCACCTTCTGTTATGAATGCTGGAGGA 
CSJ600 ATATATACTAGTTTCATGGGTTCCCCTTCTGTTATGAATGCTGGAGGA 
CSJ601 ATATATACTAGTTTCATGGCTTCCCCTTCTGTTATGAATGCTGGAGGA 
CSJ602 ATATATACTAGTTTCATGTCTTCCCCTTCTGTTATGAATGCTGGAGGA 
CSJ603 ATATATACTAGTTTCATGACTTCCCCTTCTGTTATGAATGCTGGAGGA 
CSJ604 ATATATACTAGTTTCATGTCCCCTTTGGTTATGAATGCTGGAGGAGTTC 
CSJ605 ATATATACTAGTTTCATGCCATCTTTGGTTATGAATGCTGGAGGAGTTC 
CSJ606 ATATATACTAGTTTCATGGGTACTCTAGTAGGAGGAGGGGGTGGAG 
CSJ607 ATATATACTAGTTTCATGGTTACTCTAGTAGGAGGAGGGGGTGGAG 
CSJ608 ATATATACTAGTTTCATGTGTACTCTAGTAGGAGGAGGGGGTGGAG 
CSJ616 ATATATACTAGTTTCATGCCAACTCTAGTAAATGGTGGAGGAGGGGGT
GGAGTTC 
CSJ617 ATATATACTAGTTTCATGCCAACTCTAGTAAATGCTGGAGGAGGGGGT
GGAGTTC 
CSJ618 ATATATACTAGTTTCATGCCAACTCTAGTAAATTCTGGAGGAGGGGGTG
GAGTTC 
CSJ619 ATATATACTAGTTTCATGCCAACTCTAGTAAATACTGGAGGAGGGGGT
GGAGTTC 
CSJ620 ATATATACTAGTTTCATGCCAACTCTAGTAAATTGTGGAGGAGGGGGT
GGAGTTC 
CSJ621 ATATATACTAGTTTCATGCCAACTCTAGTAAATGTTGGAGGAGGGGGT
GGAGTTC 
CSJ622 ATATATACTAGTTTCATGCCAACTCTAGTAAATTTGGGAGGAGGGGGT
GGAGTTC 
CSJ623 ATATATACTAGTTTCATGCCAACTCTAGTAAATTATGGAGGAGGGGGT
GGAGTTC 
CSJ624 ATATATACTAGTTTCATGCCAACTCTAGTAAATTGGGGAGGAGGGGGT
GGAGTTC 
53 
 
CSJ625 ATATATACTAGTTTCATGCCAACTCTAGTAAATGATGGAGGAGGGGGT
GGAGTTC 
CSJ626 ATATATACTAGTTTCATGCCAACTCTAGTAAATGAAGGAGGAGGGGGT
GGAGTTC 
CSJ627 ATATATACTAGTTTCATGCCAACTCTAGTAAATAATGGAGGAGGGGGT
GGAGTTC 
CSJ628 ATATATACTAGTTTCATGCCAACTCTAGTAAATCAAGGAGGAGGGGGT
GGAG 
CSJ629 ATATATACTAGTTTCATGCCAACTCTAGTAAATCATGGAGGAGGGGGT
GGAGTTC 
CSJ630 ATATATACTAGTTTCATGCCAACTCTAGTAAATAAAGGAGGAGGGGGT
GGAGTTC 
CSJ631 ATATATACTAGTTTCATGCCAACTCTAGTAAATATTGGAGGAGGGGGT
GGAGTTC 
CSJ632 ATATATACTAGTTTCATGCCAACTCTAGTAAATATGGGAGGAGGGGGT
GGAGTTC 
CSJ633 ATATATACTAGTTTCATGCCAACTCTAGTAAATCCAGGAGGAGGGGGT
GGAGTTC 
CSJ634 ATATATACTAGTTTCATGCCAACTCTAGTAAATTTTGGAGGAGGGGGTG
GAGTTC 
CSJ635 ATATATACTAGTTTCATGCCAACTCTAGTAAATAGAGGAGGAGGGGGT
GGAGTTC 
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